Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo silencing of alpha-synuclein using naked siRNA

1 Jan 2008

Abstract excerpt

BACKGROUND: Overexpression of alpha-synuclein (SNCA) in families with multiplication mutations causes parkinsonism and subsequent dementia, characterized by diffuse Lewy Body disease post-mortem. Genetic variability in SNCA contributes to risk of idiopathic Parkinson's disease (PD), possibly as a result of overexpression. SNCA downregulation is therefore a valid therapeutic target for PD. RESULTS: We have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological disorders and treatments
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18976489
DOI: 10.1186/1750-1326-3-19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo silencing of alpha-synuclein using naked siRNAPMID 18976489Read ↗

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseSemantic proximity Read ↗

CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson’s diseaseSemantic proximity Read ↗

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseSemantic proximity Read ↗

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s diseaseSemantic proximity Read ↗

<i>SNCA</i> -targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse modelSemantic proximity Read ↗

CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo.Semantic proximity Read ↗

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse ModelSemantic proximity Read ↗

Neuronal titration of <i>Snca</i> via enhancer disruption mitigates disease onset in a Parkinson’s disease mouse modelSemantic proximity Read ↗

α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicitySemantic proximity Read ↗

Preclinical Development of a Vectorized Artificial miRNA Gene Therapy for TauopathiesSemantic proximity Read ↗

Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi.Semantic proximity Read ↗

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.